I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Hyperbaric oxygen (HBO) therapy is U.S. Food and Drug Administration (FDA) approved for pathologies including select wounds, thermal burns, and delayed radiation injury with emerging research suggesting promise in other pathologies.[@ref1][@ref2][@ref3] HBO promotes neovascularization, modulates the inflammatory system, and promotes stem cell recruitment resulting in accelerated tissue regeneration.[@ref1][@ref3][@ref4][@ref5] Treatments involve repetitive exposures (*i.e*., intermittent hyperoxia, IH), of up to 60 sessions, of high concentrations of oxygen, together with increased atmospheric pressure of up to 3.0 atmospheres absolute (ATA; 1 ATA = 760 mmHg/101.325 kPa). HBO has a direct effect on activated endothelial cells *in vitro* including downregulating genes involved in adhesion, angiogenesis, inflammation and oxidative stress but upregulating angiogenin, which promotes both angiogenesis and nitric oxide production.[@ref6] Moreover, exposure of endothelial cells to HBO enhances capillary tube formation and oxidative stress resistance.[@ref7] However, the extent to which high pressure in HBO treatments is critical for therapeutic effect is not entirely known, and at least one *in vitro* experiment showed that HBO at 1.5 ATA induces a stronger anti-inflammatory response when compared to 2.4 ATA.[@ref8]

The effectiveness of HBO therapy may depend on some key factors including treatment dose selection (oxygen tension and duration) and patient pathology.[@ref9][@ref10] The mechanism of HBO treatment includes the production of reactive oxygen species, which results in a large number of responses including growth factor production, stem progenitor cell (S/PC) mobilization, and reduced inflammation.[@ref11][@ref12][@ref13] The increased atmospheric pressure reduces gas volume, which is instrumental in ameliorating pathological conditions such as arterial gas embolism and decompression sickness. However, these are not the majority of patients presenting in a clinical HBO setting. In addition, HBO treatment requires an expensive hyperbaric chamber, trained staff, and additional safety considerations. IH can also be delivered by exclusively increasing the oxygen concentration without changing the atmospheric pressure, referred to as normobaric oxygen (NBO). At sea level the partial pressure of oxygen is about 150 mmHg (1 mmHg = 0.1333 kPa) depending on the humidity. The resulting arterial partial pressure (PaO~2~) is 75--100 mmHg. At 100% O~2~ the transcutaneous oxygen pressure raises from 150 mmHg up to 470 mmHg.[@ref14] Moreover, this single dose of oxygen increases the expression of erythropoietin in the serum of patients,[@ref14][@ref15] increases reactive oxygen species formation followed by an increased production of glutathione.[@ref15][@ref16] However, it is unknown if NBO promotes S/PC mobilization or modulates cytokine production similar to HBO therapy.[@ref4][@ref17][@ref18][@ref19][@ref20][@ref21] Therefore, the goal of this study was to examine the efficacy of NBO focusing on mobilization of S/PCs and the expression of serum cytokines. We hypothesized that NBO would show biological effects similar to those previously reported for HBO.[@ref8][@ref18]

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Animals {#sec2-1}
-------

Twelve 10-week-old male Sprague-Dawley rats were randomly divided into two groups, a control group (*n* = 6) and a NBO treatment group (*n* = 6). Chow and water were provided ad libitum. Housing was temperature controlled at 23°C with a 12-hour/12-hour light-dark cycle. All experiments and procedures were approved by Institutional Animal Care and Use Committee (IACUC) of the University of Wisconsin, Madison, WI, USA (approval No. M005439) on June 28, 2016.

IH exposure {#sec2-2}
-----------

Animals were exposed to NBO or room air (normoxia) in clear polypropylene exposure chambers (Coy Laboratories, Grass Lake, MI, USA). The treatment group was exposed for 2 hours daily for a total of 10 hours over 5 days to an inhaled partial pressure of oxygen (P~I~O~2~) = 300 mmHg (42% O~2~ at 1 ATM). The oxygen concentration was monitored and maintained continuously during the NBO exposure. Control animals were concurrently exposed in identical chambers with the doors opened to room air.

Sample collection {#sec2-3}
-----------------

Samples were collected 24 hours after the final 2-hour hyperoxia exposure. Animals were anesthetized with isoflurane and 8--10 mL of blood was drawn from the inferior vena cava using a 21-gauge needle and a heparinized 10 mL syringe. Blood was transferred to tubes and centrifuged at 2000 r/min for 10 minutes. Plasma was collected, flash frozen in liquid Nitrogen, and then stored at --80°C until further analysis. Red blood cells were lysed using ammonium chloride. The remaining cells were washed twice with phosphate buffer saline and the cell number was determined using a Beckman Coulter Z1 Particle Counter (Beckman Coulter Life Sciences, Indianapolis IN, USA). 1 × 10^6^ cells were used for each control and sample staining for flow cytometry.

Flow cytometry {#sec2-4}
--------------

1 × 10^6^ cells in 100 µL flow buffer (phosphate buffer saline 1% albumin) were used for each staining. 5 to 10 µL antibody was added to each tube, mixed, and incubated for 30 minutes in the dark at 4°C. Then cells were washed twice and then fixed with 4% formaldehyde for 30 minutes, washed with flow buffer and stored at 4°C until analyzed the following day. The following antibodies were used: anti-CD34-PE (Abcam, Cambridge, MA, USA), anti-CD45-APC (eBioscience, Grand Island, NY, USA), and anti-CD133-DyLight 488 (Novus, Littleton, CO, USA). For live and dead cell discrimination, Ghost-Dye-V450 was used (Tonbo Bioscience, San Diego, CA, USA).[@ref22]

Flow cytometry was performed on a BD LSRII (BD Biosciences, San Jose, CA, USA) using DIVA software (BD Biosciences). Samples were analyzed using FlowJo software (FlowJo, Ashland, OR, USA). Lymphocytes were gated by forward and side scatter (**[Figure 1A](#F1){ref-type="fig"}**), doublets were excluded (**[Figure 1B](#F1){ref-type="fig"}**), and live cells were selected for further analysis (**[Figure 1C](#F1){ref-type="fig"}**). CD45 positive cells were selected (**[Figure 1D](#F1){ref-type="fig"}**) for further analysis of the expression of CD34 and CD133 (**[Figure 1E](#F1){ref-type="fig"}** and **[F](#F1){ref-type="fig"}**).

![Flow cytometry gating strategy.\
Note: (A--F) Lymphocytes were gated by forward and side scatter (A), doublets were excluded (B), and live cells were selected for further analysis (C). CD45 positive cells were selected (D) for further analysis of the expression of CD34 and CD133 (E, F).](MGR-9-139-g001){#F1}

Enzyme linked immunosorbent assay {#sec2-5}
---------------------------------

We determined the expression of selected cytokines using the Signosis Rat Cytokine enzyme linked immunosorbent assay Plate Array I (Signosis Inc., Santa Clara, CA, USA). Samples were thawed and immediately prepared for enzyme linked immunosorbent assay per manufacturer's instructions. Cytokine concentration was determined according to manufacturer's instructions using a microplate reader at 450 nm within 30 minutes.[@ref23]

The cytokines measured in this experiment include tumor necrosis factor (TNF)-α, vascular endothelial growth factor, fibroblast growth factor-β, interferon-γ, leptin, monocyte chemotactic protein-1, stem cell factor, macrophage inflammatory protein (MIP)-1α, interleukins-1α, -1β, -5, -6, -15, -10, Rantes, and transforming growth factor-β.

Statistical analysis {#sec2-6}
--------------------

All statistics were calculated using Graph Pad Prism version 6.07 (GraphPad Software, San Diego, CA, USA). All comparisons between the control group and the NBO group were performed using the non-parametric Mann--Whitney *U* test with a *P* of \< 0.05 to indicate a difference between the groups.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Cytokine expression in IH exposed rats {#sec2-7}
--------------------------------------

As previously described six rats were exposed to normoxia (150 mmHg P~I~O~2~) and six rats to NBO at 300 mmHg P~I~O~2~. Data from all study animals were used to determine the effect of NBO on cytokine expression. Our results revealed a significant decrease in TNF-α expression (**[Figure 2A](#F2){ref-type="fig"}**). We noted possible trends in two other cytokines, a decrease in MIP-1α (*P* = 0.07; **[Figure 2B](#F2){ref-type="fig"}**) and a decrease in Leptin (*P* = 0.09; **[Figure 2C](#F2){ref-type="fig"}**). Complete results from all cytokines tested are included in **[Figure 2D](#F2){ref-type="fig"}**.

![Cytokine expression in intermittent hyperoxia exposed rats.\
Note: (A) Tumor necrosis factor (TNF)-α; (B) macrophage inflammatory protein (MIP)-1α; (C) leptin; (D) Other cytokines. Data are expressed as the mean ± SD. \**P* \< 0.05 (non-parametric Mann Whitney test). VEGF: Vascular endothelial growth factor; FGF: fibroblast growth factor; IFN: interferon; MCP-1: monocyte chemotactic protein-1; SCF: stem cell factor; IL: interleukin; TGF: transforming growth factor.](MGR-9-139-g002){#F2}

Increased frequency of CD133^+^ S/PCs after IH exposure {#sec2-8}
-------------------------------------------------------

The frequency of CD133^+^/CD45^+^ and CD133^+^/CD45^+^/CD34^-^ S/PCs in venous blood was significantly increased in NBO animals compared to controls (*P* = 0.046 and *P* = 0.009 respectively; **[Figure 3](#F3){ref-type="fig"}**) whereas there was no difference in the frequency of CD34^+^/CD45^+^ or CD34^+^/CDCD133^+^/CD45^+^ S/PCs between the two groups.

![Frequency of CD133^+^ stem progenitor cells after intermittent hyperoxia exposure detected by flow cytometry.\
Note: (A) CD34^+^/CD45^+^ and CD133^+^/CD45^+^ stem progenitor cells; (B) CD34^+^/ CD133^-^/CD45^+^ and CD133^+^/CD34^+^/CD45^+^ stem progenitor cells. Data are expressed as the mean ± SD. \**P* \< 0.05 (non-parametric Mann--Whitney *U* test).](MGR-9-139-g003){#F3}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The present study assessed whether repeated NBO exposures induce biological responses that have been previously observed with HBO therapy, including S/PC mobilization and inhibition of TNF-α expression. The main finding of the study is that in adult rats, daily 2-hour exposures to NBO (for a total of 10 hours) mobilizes S/PCs and reduces serum TNF-α concentration supporting our hypothesis.

The field of therapeutic IH is dominated by the use of HBO, and HBO therapy is approved by the FDA to treat 15 indications.[@ref24] Additionally, although not FDA approved for these indications, studies appear to suggest that HBO therapy may ameliorate other conditions including myocardial infarction,[@ref25] hip fractures,[@ref26][@ref27][@ref28][@ref29][@ref30] stroke,[@ref3][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37] peri-surgical healing,[@ref38][@ref39][@ref40][@ref41][@ref42] and traumatic brain injury.[@ref3][@ref35][@ref43][@ref44][@ref45][@ref46]

It is a long standing practice to use up to 1.4 ATA of hyperbaric air resulting in the alveoli PaO~2~ of 209 mmHg as a sham in HBO research.[@ref47][@ref48][@ref49][@ref50][@ref51][@ref52] However, the rational for the use of hyperbaric air as a sham remains only partially elucidated because of lack of data defining an exact "dose" (determined by tension and duration).[@ref53] In this experiment we used a PaO~2~ of 300 mmHg which resulted in biologic activity, suggesting that the PaO~2~ used as a sham in HBO research could in fact induce a treatment effect. Further, the results suggest that increased pressure may not be required to elicit an effect. NBO therapy increases the transcutaneous oxygen concentration from 150 to 470 mmHg during a single treatment resulting in a biological response with increased erythropoietin levels.[@ref14][@ref15] This is in accordance with our study showing biologic activity resulting in changes in S/PC mobilization and inflammatory cytokine levels.

Similar to the uncertainty of the O~2~ tension required to achieve a biological and regenerative response in HBO, the tension of O~2~ required in NBO is also not clear. The intermittent exposure to HBO P~I~O~2~ of 1473 mmHg and higher mobilizes CD34^+^ S/PCs in humans. Our findings are similar demonstrating that NBO with a P~I~O~2~ of 300 mmHg induces the mobilization of S/PCs (CD133^+^) and decreases expression of TNF-α in rats.[@ref4][@ref18][@ref54][@ref55] Another study investigating two oxygen doses, P~I~O~2~ of 1473 mmHg and P~I~O~2~ of 1777 mmHg, found a direct correlation between oxygen tensions and S/PC mobilization, suggesting a dose relationship, but little is known about the effect of IH using a P~I~O~2~ ≤ 1473 mmHg.[@ref4] We used 10 treatment sessions of two hours each and achieved a visible response with 42% oxygen. This is in agreement with the observation that exposure above 40% oxygen induced an increase in derivatives of oxygen metabolites in the blood of exposed rats.[@ref56] However, more studies are required to optimize the treatment schedule for specific injury or disease models. The choice of treatment dose in this research project is based on previous research in mice using 100% oxygen at 2.8 ATA for one 90-minute treatment and another cohort for two 90-minute treatments.[@ref18] They found significant increases in S/PC mobilization in both groups and a larger increase in the two-treatment group over the single-treatment group, suggesting a dose effect. Given the likelihood of a dose effect in the current experiment provided by repeated exposure to NBO, we utilized 42% oxygen in the treatment condition because it was double the FIO~2~ compared to room air with a relatively small increase in oxygen tension. This is comparable to the small increase in oxygen utilized as a sham in previous studies investigating mild traumatic brain injury and post-traumatic stress disorder.[@ref47][@ref48][@ref49][@ref50]

Whereas the best tension and duration of oxygen treatment for various pathologies needs to be established, a common finding is the mobilization of S/PCs. We focused on CD133^+^ S/PC's based on a study by Nakanishi et al.[@ref57] showing that CD133^+^ S/PC supported the neovascularization of skin graft. In addition, CD133^+^ S/PCs differentiated into endothelial and myogenic lineages in a rat model of muscle injury[@ref58] and circulating CD133^+^ cells enhance angiogenesis, astrogliosis, axon growth and functional recovery in a mouse spinal cord injury model.[@ref59] Other tissue specific stem cells may be important for the effect of HBO and NBO treatment, a topic that needs more research.

One of the major effects of HBO treatment is the control of inflammation. This is in part achieved by the increase in reactive oxygen species production associated with oxygen therapy which play central roles in coordinating cell signaling and anti-oxidant protective pathways.[@ref12] Somewhat unexpected is the observed downregulation of TNF-α with NBO treatment in our study. This downregulation is unlikely to be explained by a reduction in existing inflammation given that the animals were healthy and no injury model was tested. One possibility is that NBO induced an inflammatory response which was downregulated within 24 hours after treatment to a level that is below basal level.[@ref8]

Our study demonstrated that IH using NBO at much lower P~I~O~2~ pressure than previously tested shows a biological response with S/PC mobilization and changes in cytokine expression similar to HBO. Future research examining oxygen/dose relationship is needed to further elucidate the biological effect of various doses of IH, and ascertain differences between concentration and pressure, along with establishing basal active levels of IH. In addition, future studies will be needed to test for efficacy in an injury model. The significance of this study is twofold. First, relatively small increases of IH yield a measurable change in S/PC mobilization and pro-inflammatory cytokine expression in an animal model. Second, the use of relatively small doses in IH as a sham in oxygen therapy research should be further investigated to determine if it is a sham or a small dose treatment.
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